Report: Biogen Idec CEO predicts more brain disorders in Tysabri patients
The CEO of Biogen Idec told investors Tuesday that he expects to see more cases of a rare, fatal brain disorder in patients taking the drug Tysabri, Reuters reported Tuesday.
But James Mullen, the executive, thinks the problems are unlikely to create more regulatory problems for Tysabri, a multiple sclerosis drug pulled temporarily from the market in 2005 thanks to the brain disease.
(hope I am not pissing off Ty users by posting negative articles. I figure knowledge is power...)